Used in the prevention and treatment of rabies infection by targeting the rabies virus glycoprotein (GP), this monoclonal antibody neutralizes the virus before it can enter the central nervous system. It serves as a critical component in post-exposure prophylaxis, especially in individuals with high risk of exposure or those who are unvaccinated. Unlike traditional rabies immunoglobulins derived from human or animal serum, this recombinant antibody offers a consistent, scalable, and safer alternative with reduced risk of adverse reactions. It is administered alongside rabies vaccine to provide immediate passive immunity while the body develops active immune response. Its high specificity and potency make it suitable for use in both urban and remote settings, improving global access to effective rabies treatment.